Your session is about to expire
← Back to Search
Non-small cell lung cancer (NSCLC) for Non-Small Cell Lung Cancer
N/A
Waitlist Available
Led By Dori Beeler
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 3 months
Awards & highlights
Summary
The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Themes from qualitative interviews with patients
Secondary study objectives
Cancer caregiving tasks, consequences, and needs
Severity and impact of cancer-related fatigue (CRF)
Themes from qualitative interviews with caregivers
Trial Design
1Treatment groups
Experimental Treatment
Group I: Non-small cell lung cancer (NSCLC)Experimental Treatment1 Intervention
Non-small cell lung cancer (NSCLC) patients treated with with immune checkpoint inhibitor.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Interviews
2017
N/A
~3830
Find a Location
Who is running the clinical trial?
Atrium Health Levine Cancer InstituteOTHER
24 Previous Clinical Trials
1,799 Total Patients Enrolled
Wake Forest University Health SciencesLead Sponsor
1,266 Previous Clinical Trials
1,013,667 Total Patients Enrolled
Dori BeelerPrincipal InvestigatorAtrium Health Levine Cancer
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger